Hyperparathyroidism subsequent to radioactive iodine therapy for Graves' disease. Issue 10 (14th June 2021)

• Record Type: Journal Article
• Authors: Law, Richard H.; Quan, Daniel L.; Stefan, Andrew J.; Peterson, Edward L.; Singer, Michael C.
• Is Part Of: Head & neck. Volume 43:Issue 10(2021)
• Page Start: 2994
• Page End: 3000
• Publication Date: 2021-06-14
• Subjects: Graves' disease -- hypercalcemia -- hyperparathyroidism -- parathyroid surgery -- radioactive iodine; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.26786
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: The development of primary hyperparathyroidism (PHPT) after radioactive iodine (RAI) treatment for thyroid disease is poorly characterized. The current study is the largest reported cohort and assesses the disease characteristics of patients treated for PHPT with a history of RAI exposure. Methods: A retrospective analysis comparing patients, with and without a history of RAI treatment, who underwent surgery for PHPT. Results: Twenty‐eight of the 469 patients had a history of RAI treatment, all for Graves' disease. Patients with a history of RAI exposure had similar disease characteristics compared to control; however, patients with a history of RAI treatment had a higher rate of recurrence (7.4% vs 1.2%, p = 0.012). Conclusion: PHPT in patients with a history of RAI treatment can be approached in the same manner as RAI naive PHPT patients; however, the risk of recurrence of PHPT in RAI exposed patients may be higher.